AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Income from Non-Controlling Interests of -$20000.0 for Q1 2026, up 41.18% year-over-year from -$14166.7 in Q1 2025, and up 41.18% quarter-over-quarter from -$34000.0 in Q1 2025.
Powered by 
Analysis
AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Income from Non-Controlling Interests for 6 years, with the latest figure at -$24000.0 in Q3 2025.
- Quarterly Income from Non-Controlling Interests rose 4.0% year-over-year to -$24000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$108000.0 (up 93.24% YoY) and the FY2024 annual result came in at -$780000.0, up 78.75% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$20000.0, up from -$34000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$20000.0 in Q1 2026, with the low at -$34000.0 in Q1 2025.
- A 5-year average of -$615666.7 and a median of -$677000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2021 and 2024: Income from Non-Controlling Interests tumbled 48500.0% in 2021, then soared 97.14% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at -$4.4 million in 2021, then soared by 62.74% to -$1.6 million in 2022, then surged by 48.11% to -$850000.0 in 2023, then surged by 96.12% to -$33000.0 in 2024, then climbed by 27.27% to -$24000.0 in 2025.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$24000.0, -$17000.0, and -$34000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | AtaiBeckley | 1.60 Bn | 1.60 Bn | - | -24,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Dec 31, 2023 | -850,000.00 |
| Sep 30, 2023 | -873,000.00 |
| Jun 30, 2023 | -729,000.00 |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -1.81 Mn |
| Jun 30, 2022 | -891,000.00 |
| Mar 31, 2022 | -689,000.00 |
| Dec 31, 2021 | -4.40 Mn |